Corbus Pharmaceuticals Completes Enrollment for Phase 1b Obesity Trial (CRB-913), Data Expected Summer 2026
Summary
Corbus Pharmaceuticals announced the completion of patient enrollment for its CANYON-1 Phase 1b clinical trial of CRB-913 for obesity, with results anticipated in summer 2026.
Key Events
-
Phase 1b Trial Enrollment Completed
Corbus Pharmaceuticals announced the "Last Patient First Visit" in its CANYON-1 Phase 1b clinical trial for CRB-913 in obesity, indicating full patient enrollment.
-
Data Readout Expected Summer 2026
The 16-week, double-blind, placebo-controlled, dose-ranging study in 240 obese, non-diabetic participants is on track to be completed in summer 2026.
-
CRB-913 Targets Obesity with Novel Mechanism
CRB-913 is a once-daily oral CB1 inverse agonist, offering a potentially differentiated approach to weight loss compared to existing incretin therapies.
-
Builds on Positive Phase 1a Results
Previous Phase 1a data showed a mean 2.9% placebo-adjusted weight loss by Day 14 and a favorable safety profile, including no significant GI or neuropsychiatric issues.
Analysis
This filing signals positive operational progress for Corbus Pharmaceuticals' lead obesity candidate, CRB-913. The completion of patient enrollment for the Phase 1b CANYON-1 study de-risks the trial timeline and sets the stage for a significant data readout in summer 2026. Given the large market for obesity treatments and the company's focus on a non-incretin approach, successful trial progression is a key value driver. Investors should monitor for the upcoming Phase 1b results, which will provide further insight into CRB-913's efficacy and safety profile, building on promising Phase 1a data.
At the time of this filing, CRBP was trading at $10.24 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $180.6M. The 52-week trading range was $5.32 to $20.56. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.